ProQR Therapeutics (PRQR) Net Income (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Net Income for 14 consecutive years, with -$15.2 million the latest figure, recorded in Q1 2026.

• Quarterly Net Income fell 28.07% year-over-year to -$15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.0 million (down 52.46% YoY) and the FY2025 annual result came in at -$49.3 million, down 55.92% from the prior year.
• Net Income declined to -$15.2 million in Q1 2026 per PRQR's latest filing, from -$11.4 million in the prior quarter.
• Over the last five years, Net Income for PRQR reached as high as -$3.5 million in Q2 2024 and fell as low as -$26.4 million in Q3 2022.
• A 5-year average of -$11.9 million and a median of -$11.4 million in 2025 frame the typical range for Net Income.
• Annual changes were most pronounced in 2023 — Net Income jumped 76.6% — and 2025, when it slumped 292.72%.
• Year by year, Net Income stood at -$15.4 million in 2022, then jumped by 49.56% to -$7.7 million in 2023, then plunged by 30.95% to -$10.1 million in 2024, then decreased by 12.89% to -$11.4 million in 2025, then sank by 33.03% to -$15.2 million in 2026.
• According to Business Quant data, Net Income over the past three periods registered -$15.2 million, -$11.4 million, and -$12.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.